These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Double-blind clinical trial of protacine versus oxyphenbutazone in rheumatic disorders.
    Author: Loizzi P, Pipitone V, Bignamini AA.
    Journal: Pharmatherapeutica; 1980; 2(5):285-92. PubMed ID: 7001487.
    Abstract:
    A double-blind trial wa carried out in 30 in-patients, mainly with rheumatoid disorders, to compare the efficacy and tolerance of protacine with those of oxyphenbutazone. Patients were given oral doses either of 150 mg protacine or 200 mg oxyphenbutazone 3-times daily for 21 days. Clinical symptoms were assessed by semiquantitative scoring at 5-days' intervals. The same was done for side-effects. Protacine globally reduced the symptom scores by 55% and oxyphenbutazone by 34% (p < 0.001). Frequency and severity of side-effects were significantly less and less severe during protacine than during oxyphenbutazone treatment (p < 0.01). Physiological parameters did not vary during either treatment. Good efficacy, good tolerance and a convenient dose schedule suggest that protacine may well be suited also for long-term treatment.
    [Abstract] [Full Text] [Related] [New Search]